Topelia is focused on the rapid and efficient development of antiviral therapeutics targeting coronavirus infections

Learn More

About Topelia

Topelia Aust Limited (ABN 36 652 771 670) (Topelia) is an unlisted biotechnology company focused on developing and commercialising its proprietary Antiviral Triple Therapy (ATT) for coronavirus infection.
Learn More
 

Covid-19 The Global Pandemic

While most patients diagnosed with COVID-19 develop only mild to moderate disease, approximately 25% will progress to severe/critical disease state requiring medical intervention and mechanical ventilation with poor prognosis for disease resolution in severe or critical cases. These sorts of outcomes are particularly seen in the elderly and those with co-morbidities4.

Learn More

Latest News

Why Invest?

Topelia is developing and commercialising its proprietary Antiviral Triple Therapy (ATT) for coronavirus infection.

Read More

Therapeutics: Our partnerships and collaborations

Topelia has built strong partnerships with a group of world-leading experts with unique knowledge sets and strong resourcing that will guide Topelia in developing its proprietary Antiviral Triple Therapy (ATT) for coronavirus infection.

Read More

Our Pipeline

Topelia will initially focus on the development of its TPL101 Antiviral Triple Therapy for coronavirus infection.

Topelia sees a range of potential uses for TPL101 in coronavirus infection.

Learn More

Meet the Team

Prof Thomas Borody

Co-founder and Research Director

Dr Sabine Hazan

Co-founder and Microbiome Research Director

Rodney Unsworth

Non-Executive Chairman

Dr David Fox

CEO

Graham Sorensen

Director

Professor Robert Clancy (AM)

BSc Med (Hons) MBBS (Hons) PhD DSc FRACP FRCPA

View all team

SUBSCRIBE TO OUR NEWSLETTER

Stay in touch with us to get latest news and announcements.